Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CytomX Therapeutics ( (CTMX) ) has issued an update.
On June 11, 2025, CytomX Therapeutics held its Annual Meeting of Stockholders, where key amendments to the company’s equity and stock purchase plans were approved. The amendments included increasing the number of shares available under the 2015 Equity Incentive Plan, removing the evergreen provision, and extending the Employee Stock Purchase Plan indefinitely. Additionally, stockholders elected new directors, ratified the selection of Ernst & Young LLP as the independent auditor, and approved executive compensation.
The most recent analyst rating on (CTMX) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on CytomX Therapeutics stock, see the CTMX Stock Forecast page.
Spark’s Take on CTMX Stock
According to Spark, TipRanks’ AI Analyst, CTMX is a Neutral.
CytomX Therapeutics demonstrates strong technical momentum and an attractive valuation, contributing positively to its score. The company’s ability to regain Nasdaq compliance and secure significant funding also boosts its financial stability and market confidence. However, financial performance is weighed down by balance sheet weaknesses and cash flow challenges, which present ongoing risks.
To see Spark’s full report on CTMX stock, click here.
More about CytomX Therapeutics
CytomX Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of novel therapeutics for the treatment of cancer. The company utilizes its proprietary Probody therapeutic platform to create innovative cancer treatments.
Average Trading Volume: 4,709,277
Technical Sentiment Signal: Buy
Current Market Cap: $444.3M
See more insights into CTMX stock on TipRanks’ Stock Analysis page.